Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Stock Short Interest Declines 87.1%

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) saw a significant drop in short interest in September. As of September 30th, there was short interest totaling 10,544 shares, a drop of 87.1% from the September 15th total of 81,947 shares. Based on an average daily volume of 215,472 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.2% of the company’s stock are sold short.

Chemomab Therapeutics Stock Performance

Shares of NASDAQ CMMB opened at $1.38 on Friday. The company’s fifty day moving average price is $2.13 and its 200 day moving average price is $1.84. Chemomab Therapeutics has a 1 year low of $1.05 and a 1 year high of $3.50. The company has a market capitalization of $10.01 million, a PE ratio of -0.65 and a beta of 0.74.

Chemomab Therapeutics (NASDAQ:CMMB) last released its quarterly earnings data on Thursday, August 20th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.12).

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Wall Street Zen raised shares of Chemomab Therapeutics to a “hold” rating in a research report on Saturday, October 3rd. Weiss Ratings upgraded Chemomab Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 16th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Chemomab Therapeutics has a consensus rating of “Reduce”.

Hedge Funds Weigh In On Chemomab Therapeutics

A hedge fund recently raised its position in Chemomab Therapeutics stock. Kestra Private Wealth Services LLC boosted its holdings in shares of Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) by 19.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 61,710 shares of the company’s stock after purchasing an additional 10,000 shares during the quarter. Kestra Private Wealth Services LLC owned approximately 0.86% of Chemomab Therapeutics worth $97,000 at the end of the most recent reporting period. 46.05% of the stock is owned by institutional investors and hedge funds.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory and fibrotic diseases. The company’s research is centered on CCL24, a chemokine believed to contribute to inflammation, fibrosis and tissue damage across several disease areas.

Chemomab’s lead product candidate is CM-101, a proprietary monoclonal antibody designed to block CCL24 activity. The therapy has been evaluated in clinical studies for conditions including primary sclerosing cholangitis, a progressive liver disease, and systemic sclerosis, an autoimmune disorder that can cause widespread fibrosis.